| Literature DB >> 35247083 |
Francesca Velarde1,2,3,4, Sarah Ezquerra1,2,3, Xavier Delbruyere1,2,3, Andres Caicedo5,6,7,8, Yessia Hidalgo9,10,11, Maroun Khoury12,13,14.
Abstract
There is a steadily growing interest in the use of mitochondria as therapeutic agents. The use of mitochondria derived from mesenchymal stem/stromal cells (MSCs) for therapeutic purposes represents an innovative approach to treat many diseases (immune deregulation, inflammation-related disorders, wound healing, ischemic events, and aging) with an increasing amount of promising evidence, ranging from preclinical to clinical research. Furthermore, the eventual reversal, induced by the intercellular mitochondrial transfer, of the metabolic and pro-inflammatory profile, opens new avenues to the understanding of diseases' etiology, their relation to both systemic and local risk factors, and also leads to new therapeutic tools for the control of inflammatory and degenerative diseases. To this end, we illustrate in this review, the triggers and mechanisms behind the transfer of mitochondria employed by MSCs and the underlying benefits as well as the possible adverse effects of MSCs mitochondrial exchange. We relay the rationale and opportunities for the use of these organelles in the clinic as cell-based product.Entities:
Keywords: Cell-based therapy; Mesenchymal stem/stromal cells; Mitochondria; Mitochondrial transfer
Mesh:
Year: 2022 PMID: 35247083 DOI: 10.1007/s00018-022-04207-3
Source DB: PubMed Journal: Cell Mol Life Sci ISSN: 1420-682X Impact factor: 9.261